Diseases and Drugs


lyrica-july29.jpg After having had a banner year for new drug approvals in 2018, hitting a record number of 59, it looks like the pace of FDA approval is slowing down this year. Only 16 new drugs have been greenlighted so far this year compared to 26 during the same period last year. Let's take a look at the companies that await a ruling from the FDA in August 2019.

opioids-july23.jpg The opioid crisis in the United States has grown at an alarming rate. It is estimated that more than 300,000 Americans have died of an opioid overdose since 2000. Among the American states, Alabama has the highest rate of opioid prescriptions - with healthcare providers writing 107.2 opioid prescriptions for every 100 persons. West Virginia has the highest rate of death due to drug overdose.

fdaapproval-march25.jpg On July 1 of this year, the regulator eliminated the REMS for Truvada and its generics. According to FDA, now, after seven years, vast majority of health care professionals and at-risk individuals are aware of the risks and prevention methods of HIV infection, and educational materials and treatment guidelines are readily available at the U.S. Centers for Disease Control and Prevention.

emgality-jun26.jpg So far this year, i.e, January to June, only 12 novel drugs have been approved compared to 20 during the same period last year. Now, let's take a look at the biotech stocks awaiting the U.S. regulatory decision in July.

beware-jun12.jpg Everyone dreads catching a viral infection. The word "virus" has its origin in Latin, which means slimy liquid or poison, and it has been associated with a number of disease outbreaks, epidemic, and pandemic. Now, let's take a look at some of the viruses that are posing a constant threat to mankind.

fdaapproval-march25.jpg Spinal muscular atrophy or SMA is a genetic disease affecting the part of the nervous system that controls voluntary muscle movement.

orofacialpain-jun07.jpg The sensation of pain is an unpleasant feeling. It is a signal sent out by the central nervous system, warning the body that something is wrong. According to the American Association of Neurological Surgeons, the disorder associated with the most excruciating pain known to humanity is trigeminal neuralgia, also known as tic douloureux.

fragmin-052419.jpg As another month comes to a close, it's time to take a look back at some of the pharma news stories of May, and look ahead at what's coming next over the horizon on the regulatory front.

fdaapproval-march25.jpg A disease that affected 9 countries in the world a few decades ago, dengue has now become endemic, affecting nearly half of the global population.

collage-april26.jpg A lot happened in the month of April, from the resignation of FDA Commissioner Scott Gottlieb coming into effect to the launch of the world's first malaria vaccine. Now, let's take a look at the companies that await a ruling from the FDA in May 2019.

fdaapproval-march25.jpg On April 8, the FDA approved Dovato, a two-drug regimen of dolutegravir (DTG) 50 mg and lamivudine (3TC) 300 mg for the treatment of HIV-1 infection in adults with no antiretroviral treatment history.

anaptysbio-april12.jpg Peanut allergy, a condition in which the immune system mistakenly recognizes a number of proteins from peanuts as potential foreign pathogens, triggering an inflammation, is most common in children. The rate of peanut allergy is on the rise - with approximately 2 percent of children, roughly 1.5 million children in the U.S., being affected, according to the Jaffe Food Allergy Institute.

customersurprised-april03.jpg It typically takes 10-12 years to introduce a new drug into the market - i.e., from the initial discovery stage to regulatory approval - and it costs the drugmakers an average of $2.6 billion.

fda-march26.jpg So far this year, 4 novel drugs have been approved in the U.S., including Zulresso. Now, let's take a look at the companies that await a ruling from the FDA in April 2019.

fdaapproval-march25.jpg Postpartum depression, or PPD, is a mood disorder that can affect women after childbirth. In the U.s., estimates of new mothers identified with PPD each year vary by state from eitht to 20/%, with an overall average of 11.5%.

Follow RTT